A cilostazol hatékony és biztonságos lehetőség a                     claudicatio intermittens kezelésére. <i>A NOCLAUD vizsgálat                         eredményei</i>

Farkas, Katalin; Járai, Zoltán

doi:10.1556/650.2017.30660

Cited by 7 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heart rate did not change significantly in any of the patients from the GAS2 group. More frequent occurrence of side effects on the background of C and drug withdrawal in our study compared with the data of a multicenter study (8.1 and 1.7%, respectively) [3], which included patients with ICS, may be due to multifocal vascular lesions in our study.…”

Section: Rs Globalsupporting

confidence: 47%

“…This coincided with an increase in the painless walking distances and maximum walking, respectively, from (172.5±41.3) to (305.0±44.9)m (by 76.8%; p<0.01) and from (395,1±90.2) to (563.1±85.4)m (by 42.5%; p<0.01). The data is somewhat expected: most studies evaluating the effectiveness of C in patients with LEAD indicate an increase in walking distances against the background of its use [1,2,3,10]. In the GAS2 group, 16.1% (5 of 31) patients had a reduction in lower extremity pain during walking.…”

Section: Rs Globalmentioning

confidence: 89%

See 1 more Smart Citation

The Effectiveness of Cilostazol in Patients With Generalized Atherosclerosis

Motsak

Lizogub

Kupchynska

et al. 2020

RS Global - World Science

View full text Add to dashboard Cite

The aim of the study is to investigate the effectiveness of cilostazol in patients with generalized atherosclerosis (GAS).A comprehensive examination of 65 male patients with proved GAS was performed (lesions of the lower extremities, carotid, mesenteric, coronary, cerebral arteries) and 28 healthy males (comparison group - CG) aged over 60 years. Patients with GAS consisted of 2 groups: GAS1 - patients in addition to basic therapy received cilostazol (C; 100 mg 2 times per day); GAS2 - placebo. Patients with GAS showed a significant deterioration in blood flow (decrease in its volumetric blood flow - FV, increase in peak systolic velocity - PSV) in all studied arteries, episodes of myocardial ischemia according to daily ECG monitoring, decreased cognitive function (CF). In patients with GAS1 on the background of taking C observed improvement (p<0,001) blood flow in the studied arteries (increase in FV and decrease in PSV), decrease in the number and duration of episodes of myocardial ischemia (p<0,01 and p<0,05, respectively), increase distances of painless and maximum walking distance (p<0,01), improvement of CF. The data obtained indicate the effectiveness of C as part of complex therapy in patients with GAS and expediency of further research in this direction to clarify the criteria for its appointment to such patients.

show abstract

Section: Rs Globalsupporting

confidence: 47%

Section: Rs Globalmentioning

confidence: 89%

The Effectiveness of Cilostazol in Patients With Generalized Atherosclerosis

Motsak

Lizogub

Kupchynska

et al. 2020

RS Global - World Science

View full text Add to dashboard Cite

show abstract

“…To examine whether pharmacologically targeting the meningeal system improves ICH outcomes, we used cilostazol, a Food and Drug Administration-approved phosphodiesterase inhibitor that has been shown to improve lymphatic function. 31,32 At day 3 post-ICH, we observed increased branching number in mLVs at the left (35.3±15.3 versus 15.7±4.7, P =0.001) and right transverse sinus (39.6±13.3 versus 23.3±10.5, P =0.008) after cilostazol treatment compared with the vehicle carboxymethyl cellulose-treated group (Figure 5A). We also observed an increase in PKH-26 fluorescence intensity at the left (7.3±2.0 versus 4.9±1.8, P =0.013) and right transverse sinus (8.4±3.0 versus 4.9±2.1, P =0.008), suggesting an increased uptake of red blood cells (RBCs) into the lymphatic vessels in the cilostazol group (Figure 5B).…”

Section: Resultsmentioning

confidence: 94%

“…[5][6][7][8][44][45][46] As such, we used cilostazol to test whether pharmacologically targeting the meningeal lymphatic system promoted hematoma resolution and ultimately aided in ICH recovery. We found that treatment with cilostazol, a Food and Drug Administration-approved drug shown to improve peripheral lymphatic function, 31,32 advanced the natural course of meningeal lymphangiogenesis following ICH. Enhancement in lymphatic drainage of RBCs into the dCLNs through mLVs paralleled reduced hematoma volume, less long-term neuron loss and astrogliosis in addition to improving functional outcome in the cilostazol-treated ICH animals.…”

Section: Discussionmentioning

confidence: 96%

Functional Investigation of Meningeal Lymphatic System in Experimental Intracerebral Hemorrhage

Tsai

Hsieh

Lin

et al. 2022

Stroke

View full text Add to dashboard Cite

Background: Promotion of hematoma resolution in a timely manner reduces intracerebral hemorrhage (ICH) brain injury induced by toxic blood components and subsequent neuroinflammation. The meningeal lymphatic system is responsible for clearance of macromolecules and pathogenic substances from the central nervous system; however, its role in intraparenchymal hematoma clearance and ICH outcomes is unknown. In the present study, we aimed to understand the contribution of the meningeal lymphatic system to ICH pathologies and to test whether pharmacological enhancement of meningeal lymphatic function promotes hematoma resolution and brain recovery after ICH. Methods: Immunofluorescence of whole-mount meninges was used to measure complexity and coverage level of meningeal lymphatic vasculature following ICH induction. Fluorescent microbeads and PKH-26-labeled erythrocytes were used to evaluate drainage function of the meningeal lymphatic system. Visudyne treatment, deep cervical lymph node ligation, and VEGF (vascular endothelial growth factor)-C injection were performed to manipulate meningeal lymphatic function. Neurobehavioral performance and hematoma volume were assayed by the cylinder test and histological measurements. Iron deposition, residual erythrocytes, neuronal loss, and astrogliosis were assessed by immunohistochemistry and antibody-based fluorescence staining. Results: Meningeal lymphangiogenesis and enhanced lymphatic drainage occurred during the late phase of ICH. Ablation and blockage of meningeal lymphatic vessels impeded hematoma clearance, whereas pharmacological enhancement of their function reduced hematoma volume, improved behavioral performance, and reduced brain residual erythrocytes, iron deposition, neuronal loss, and astroglial activation. Conclusions: Early enhancement of meningeal lymphatic function is beneficial for ICH recovery. Targeting the meningeal lymphatic system is therefore a potential therapeutic approach for treating ICH.

show abstract

“…A cilostazol ellenjavallt szívelégtelenségben, kettős trombocitaaggregáció-gátló vagy antikoaguláns + trombocitaaggregáció-gátló kezelés mellett és súlyos veseelégtelenség (GFR <25 ml/min) esetén. 88,89…”

Section: Ajánlás 14 Cilostazol Ajánlott a Claudicatiós Tünetek Enyhítunclassified

Egészségügyi szakmai irányelv – A diabeteses láb szindrómában szenvedő cukorbetegek ellátása felnőttkorban (klinikai kép, diagnosztika, terápia, megelőzés)

Jermendy¹,

Hídvégi²,

Pécsváradi³

2018

Diabetologia Hungarica

View full text Add to dashboard Cite

A cilostazol hatékony és biztonságos lehetőség a claudicatio intermittens kezelésére. A NOCLAUD vizsgálat eredményei

Cited by 7 publications

References 19 publications

The Effectiveness of Cilostazol in Patients With Generalized Atherosclerosis

The Effectiveness of Cilostazol in Patients With Generalized Atherosclerosis

Functional Investigation of Meningeal Lymphatic System in Experimental Intracerebral Hemorrhage

Egészségügyi szakmai irányelv – A diabeteses láb szindrómában szenvedő cukorbetegek ellátása felnőttkorban (klinikai kép, diagnosztika, terápia, megelőzés)

Contact Info

Product

Resources

About